Editas Medicine 2025 Proxy Statement: Executive Pay Details

Ticker: EDIT · Form: DEF 14A · Filed: Apr 15, 2025 · CIK: 1650664

Sentiment: neutral

Topics: proxy-statement, executive-compensation, governance

TL;DR

Editas Medicine dropped its 2025 proxy statement, showing exec pay details for 2024. Check O'Neill and Mullen's compensation.

AI Summary

Editas Medicine, Inc. filed its DEF 14A on April 15, 2025, detailing executive compensation for the fiscal year ending December 31, 2024. The filing includes information on compensation for individuals such as O'Neill Member and Mullen Member, with compensation data spanning from 2022 to 2024.

Why It Matters

This filing provides shareholders with crucial information regarding how executive compensation is structured and awarded, impacting company governance and investor confidence.

Risk Assessment

Risk Level: medium — DEF 14A filings often contain information about executive compensation, potential shareholder proposals, and board nominations, which can influence stock performance and investor sentiment.

Key Numbers

Key Players & Entities

FAQ

What is the primary purpose of this DEF 14A filing for Editas Medicine, Inc.?

The primary purpose is to provide shareholders with information regarding the company's annual meeting of shareholders, including details on executive compensation, director nominations, and other corporate governance matters.

Who are the named individuals whose compensation is detailed in this filing?

The filing details compensation for individuals identified as 'O'Neill Member' and 'Mullen Member', among others, for the fiscal years 2022, 2023, and 2024.

What is the fiscal year end for Editas Medicine, Inc. as stated in the filing?

The fiscal year end for Editas Medicine, Inc. is December 31st (1231).

When was this DEF 14A filing submitted to the SEC?

This DEF 14A filing was submitted to the SEC on April 15, 2025 (20250415).

What is the Standard Industrial Classification (SIC) code for Editas Medicine, Inc.?

The Standard Industrial Classification (SIC) code for Editas Medicine, Inc. is 2836, which corresponds to Biological Products (No Diagnostic Substances).

Filing Details

This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 15, 2025 by O'Neill Member regarding Editas Medicine, Inc. (EDIT).

View full filing on EDGAR

View Full Filing

View this DEF 14A filing on SEC EDGAR

View on Read The Filing